152 Sight-Restoring Surgeries Delivered in Rural India by eMedEd & Sankara Nethralaya's "Vision for All" Eye Camp. From July 15 to 25, 2025, the "Vision for All" Mobile Eye Surgical Unit (MESU) Camp brought free cataract surgeries, post-op care, screenings, and follow-up support to...
The Healthcare Technology Report is pleased to announce The Top 25 Digital Health Executives of 2025. NEW YORK, Sept. 14, 2025 /PRNewswire-PRWeb/ -- The Healthcare Technology Report is pleased to announce The Top 25 Digital Health Executives of 2025. This year, Hinge Health's IPO, led by...
CBDNorth has been recognized as the #1 CBD oil brand in Canada by the Sarnia Journal, praised for quality, transparency, and community impact. MIAMI, Sept. 14, 2025 /PRNewswire-PRWeb/ -- CBDNorth, a Vancouver‑based brand known for its organic, lab‑tested CBD products, has been named Best...
Once fired and facing uncertainty, Caillier transformed crisis into a lasting legacy—today guiding entrepreneurs and companies to build purpose-driven empires of their own LAFAYETTE, La., Sept. 13, 2025 /PRNewswire-PRWeb/ -- Twenty years ago, as Hurricanes Katrina and Rita left...
Sepsis awareness in the U.S. has hit an all-time high of 75%, according to Sepsis Alliance's 2025 survey. This marks significant progress in public education, while exposing persistent disparities across racial, economic, and generational lines. SAN DIEGO, Sept. 13, 2025...
Dr. Jennifer Montes and Dr. Zuhaib Ibrahim Lead Collaborative, Oncoplastic Approach Using Groundbreaking Intraoperative Imaging Technology FLEMINGTON, N.J., Sept. 12, 2025 /PRNewswire-PRWeb/ -- Hunterdon Medical Center and The Institute for Advanced Reconstruction proudly announce being...
Women We Admire is pleased to announce The Top 50 Women Chief Medical Officers of 2025 NEW YORK, Sept. 12, 2025 /PRNewswire-PRWeb/ -- Women We Admire is pleased to announce The Top 50 Women Chief Medical Officers of 2025. This year's honorees lead clinical strategy for major health...
ASEA introduces ASEA Performance—a revolutionary feel-good drink kit designed to help people move, think, feel, and glow like never before. PLEASANT GROVE, Utah, Sept. 12, 2025 /PRNewswire-PRWeb/ -- ASEA Launches Reformulated ASEA Performance Line to Support Full-Body Wellness ASEA has...
The International Society for Biological and Environmental Repositories (ISBER) is pleased to announce the release of the Spanish translation of the ISBER Best Practices: Recommendations for Repositories, Fifth Edition. This is the definitive best practices guide for biological and...
64K Cellssense, a Swiss anti-aging nutrition brand, is expanding rapidly in China's supplement market, driven by biotech innovation and luxury positioning. GENEVA, Sept. 12, 2025 /PRNewswire-PRWeb/ -- Global and Regional Market Expansion The global anti-aging supplements market is...
Thera Logics Inc. has named PJ Capelli to its senior leadership team, where he will focus on building secure, scalable digital health tools to support the company's rehabilitation platform. With more than 25 years of experience in healthcare technology, Capelli's expertise aligns with...
The organization confirmed it will hold a live webinar focused on helping parents and teachers understand the developmental challenges tied to retained primitive reflexes. NAPERVILLE, Ill., Sept. 11, 2025 /PRNewswire-PRWeb/ -- Brain Balance, a leading non-medical program dedicated to...
The Melanoma Research Foundation (MRF) will host its 24th Annual New York City Gala on Thursday, October 30 at Cipriani Broadway. This inspirational event honors those in the melanoma community who are making an impact and raises critical research dollars with the unified goal of driving...
WhiteFlag has earned a coveted spot as a Venture Atlanta 2025 Showcase Company—an honor that places it among the Southeast's most promising startups, chosen through a rigorous, highly selective process at one of the largest and most respected venture conferences in the U.S. ATLANTA, Sept....
Celebrating a Culture of Care, Trust, and Teamwork To Improve the Lives of Those It Serves OMAHA, Neb., Sept. 11, 2025 /PRNewswire-PRWeb/ -- Right at Home, a global leader in professional in-home care, has been awarded the 2025 Bronze Employee Satisfaction Award by Franchise Business...
Care Star Recovery & Wellness, based in Carrollton, TX, is expanding access to holistic outpatient drug and alcohol rehab services for the greater Dallas area, offering Partial Hospitalization (PHP) and Intensive Outpatient (IOP) programs designed to treat both substance use and mental...
CleanNet of Pennsylvania provides professional commercial, office, and industrial cleaning services for businesses across the state. With customizable programs and highly trained staff, the company helps organizations maintain clean, safe, and productive workplaces, from Pittsburgh to...
Georgia Plastic & Reconstructive Surgery, led by internationally renowned, double board-certified plastic surgeon Dr. Stanley Okoro, is proud to announce that it has been designated as one of the first Centers of Excellence in the United States for Quantum RF, a groundbreaking...
Proactive support system allows users to schedule wellness calls during psychedelic experiences, eliminating barriers to accessing help when needed most SAN FRANCISCO, Sept. 10, 2025 /PRNewswire-PRWeb/ -- Fireside Project, the leading provider of psychedelic support services, today...
The market for obesity medications is growing rapidly; serious risks for people with eating disorders or disordered eating CHICAGO, Sept. 10, 2025 /PRNewswire-PRWeb/ -- As the market for GLP-1 medications continues to expand rapidly, there are serious risks for individuals at risk of or...
Today, the World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity. Medicines for cystic fibrosis, psoriasis, haemophilia and blood-related disorders are among the other additions.
WHO EML and EMLc include medicines for priority health needs of populations. They are adopted in over 150 countries, serving as a basis for public sector procurement, supply of medicines and health insurance, reimbursement schemes. The revisions mark the 24th edition of WHO EML and 10th edition of EMLc.
“The new editions of essential medicines lists mark a significant step toward expanding access to new medicines with proven clinical benefits and with high potential for global public health impact,” said Dr Yukiko Nakatani, Assistant Director-General for Health Systems, Access and Data.
Launched in 1977 largely to promote better access to medicines in developing countries, the WHO Model Lists have become a trusted global policy tool for decisions related to the selection and universal coverage of medicines within all health systems.
The WHO Expert Committee on the Selection and Use of Essential Medicines reviewed 59 applications, including 31 proposals for the addition of new medicines or medicine classes. As a result, 20 new medicines were added to the EML and 15 to the EMLc, along with new use indications for seven already-listed products. The updated lists now include a total of 523 essential medicines for adults and 374 for children, reflecting the most pressing public health needs.
Cancer is the second leading cause of death globally, claiming nearly 10 million lives each year and responsible for almost one in three premature deaths from noncommunicable diseases. Cancer treatments have been a major focus of the WHO EML for the past decade. With cancer medicines accounting today for about half of all new drug approvals by regulatory agencies, the Expert Committee applies rigorous criteria to recommend only those therapies that offer the greatest clinical benefit. As a result, few approved cancer medicines are included – only those proven to prolong life by at least 4-6 months.
Seven applications encompassing 25 cancer medicines were evaluated. As part of broader efforts to reduce inequities in cancer care, the Committee recommended increasing access to PD-1/PD-L1 immune checkpoint inhibitors, a class of immunotherapy medicines that help the body’s immune system recognize and attack cancer cells more effectively. Pembrolizumab was added to the EML as a first-line monotherapy for metastatic cervical cancer, metastatic colorectal cancer, and metastatic non-small cell lung cancer. For the latter, atezolizumab and cemiplimab are included as therapeutic alternatives.
The Committee also considered several expert-recommended strategies – highlighted in the cancer experts report – aimed at improving access to and affordability of cancer treatments. It endorsed evidence-based clinical and health system strategies, including dose optimisation approaches, to improve access. The Committee emphasized that while health system reforms require time and government action, clinical strategies can be implemented immediately to deliver faster benefits, especially in resource-limited settings.
Diabetes and obesity are two of the most urgent health challenges facing the world today. Over 800 million people were living with diabetes in 2022, with half going untreated. At the same time, more than 1 billion people worldwide are affected by obesity, and rates are rising especially fast in low- and middle-income countries. These two conditions are closely linked and can lead to serious health problems, including heart disease and kidney failure.
The WHO Expert Committee reviewed strong scientific evidence showing that a group of medicines called glucagon-like peptide-1 (GLP-1) receptor agonists can help people with type 2 diabetes – especially those who also have heart or kidney disease – by improving blood sugar control, reducing the risk of heart and kidney complications, supporting weight loss, and even lowering the risk of early death.
GLP-1 receptor agonists – semaglutide, dulaglutide and liraglutide – and the GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual receptor agonist (tirzepatide) have been added to the EML. They are used as glucose lowering therapy for adults with type 2 diabetes mellitus with established cardiovascular disease or chronic kidney disease and obesity (defined as body mass index (BMI) ≥ 30kg/m2). This provides clear guidance to countries on which patients can benefit most from these therapies.
High prices of medicines like semaglutide and tirzepatide are limiting access to these medicines. Prioritizing those who would benefit most, encouraging generic competition to drive down prices and making these treatments available in primary care – especially in underserved areas – are key to expanding access and improving health outcomes. WHO will continue monitoring developments, support fair pricing strategies, and help countries improve access to these life-changing treatments.
“A large share of out-of-pocket spending on noncommunicable diseases goes toward medicines, including those classified as essential and that, in principle, should be financially accessible to everyone,” said Deusdedit Mubangizi, WHO Director of Policy and Standards for Medicines and Health Products. “Achieving equitable access to essential medicines requires a coherent health system response backed by strong political will, multisectoral cooperation, and people-centred programmes that leave no one behind.”
More details of the Expert Committee’s recommendations, describing the additions, changes and removal of medicines and formulations, and decisions not to recommend medicines are available in the Executive Summary here.
Note to editors
The meeting of the 25th WHO Expert Committee on the Selection and Use of Essential Medicines was held at WHO Headquarters in Geneva, Switzerland, from 5 to 9 May 2025. The Expert Committee considered a total of 59 applications, assessing the scientific evidence on each medicine’s effectiveness, safety, comparative cost, and overall cost-effectiveness to inform its recommendations. The Committee also considered proposals relating to the definitions and update of the AWaRe (Access, Watch, Reserve) classification of antibiotics.
The Model Lists are updated every two years by an Expert Committee, made up of recognized specialists from academia, research and the medical and pharmaceutical professions, to address new health challenges, prioritize highly effective therapeutics and improve affordable access.